Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 2, 1995European Heart JournalOpen Access

Antiplatelet therapy in therapy-resistant unstable angina: A pilot study with REO PRO (c7E3)

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does c7E3 reduce major events in patients with therapy-resistant unstable angina undergoing angioplasty?

Population

60 patients with unstable angina refractory to intensive medical therapy, exhibiting dynamic ECG changes and…

Comparison

c7E3 bolus and infusion, combined with heparin… vs Placebo combined with heparin and aspirin

Design

RCT, randomized

Authors

MBMoshe BrandAriel UniversityMSMaarten L. SimoonsUniversity of North Carolina at Chapel HillMBM. J. de BoerUniversity Medical Center Groningen

Discussion

Loading...

Member takes

Implication

Supports c7E3 in therapy-resistant unstable angina undergoing angioplasty; extends evidence for GP IIb/IIIa inhibition in high-risk PCI.

Structured PICO

Does c7E3 reduce major events in patients with therapy-resistant unstable angina undergoing angioplasty?

P
Population
60 patients with unstable angina refractory to intensive medical therapy, exhibiting dynamic ECG changes and recurrent pain attacks, with a culprit lesion amenable for angioplasty.
I
Intervention
c7E3 (monoclonal platelet GPIIb/IIIa receptor antibody) bolus and infusion, combined with heparin and aspirin
C
Comparator
Placebo combined with heparin and aspirin
O
Outcome
Major events defined as death, myocardial infarction or urgent interventioncomposite

In patients with therapy-resistant unstable angina, c7E3 bolus and infusion significantly reduced major ischemic events compared to placebo.

Cite This Study

Brand et al. (1995) studied this question.

synapsesocial.com/papers/6a89800a4c72c4abfd621813https://doi.org/10.1093/eurheartj/16.suppl_l.36

Topics

Dual antiplatelet therapyWomen and heart disease
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.1994 · 245 citations
  2. 2Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty1993 · 71 citations
  3. 3Effects of β3-Integrin Blockade (c7E3) on the Response to Angioplasty and Intra-Arterial Stenting in Atherosclerotic Nonhuman Primates1998 · 29 citations
  4. 4Restoration of coronary blood flow by single bolus injection of the gpiib/iiia receptor antagonist c7e3 fab in a patient with acute myocardial infarction of recent onset1998 · 7 citations
  5. 5The Anti-GpIIb-IIIa Agents: Fundamental And Clinical Aspects2009 · 39 citations